[96a5a0]: / output / allTrials / logical / NCT03703427_logical.json

Download this file

609 lines (609 with data), 37.8 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
{
"info": {
"nct_id": "NCT03703427",
"official_title": "Randomised, Multicenter Phase II Study in Patients With High Risk Breast Cancer With Capecitabine Versus Vinorelbine With Pathologic Residual Tumors After Preoperative Chemotherapy Secondary ID",
"inclusion_criteria": "* 1. Female patient with primary, infiltrative breast cancer who has been diagnosed on a histological basis. 2. Stage I-IIIB at the first diagnosis and underwent curative resection. 3. The patient was non-pCR after preoperative chemotherapy including anthracycline agents and paclitaxel or docetaxel; that is, she had undergone primary tumor resection and pathologically confirmed to have residual cancer cells.The previously adminstered preoperative chemotherapy must have involved 8 cycles of EC-T or 6 cycles of TEC.If HER-2 is positive, trastuzumab is applied with T chemotherapy 4. The patient has high risk: young;triple negtive breast caner; positive axillary lymphnode;HER-2 positive;ect 5. The patient's general performance status is 0 to 1. 6. The patient must have no carry-over of efficacy from any previous treatment. 7. The patient has maintained sufficient organ function to permit valid evaluation. 8. The patient must have no adverse drug reactions of grade 2 or higher carried over from previous treatment. 9. The patient's creatinine clearance is higher than 50 ml/min 10. The patient has personally given written, informed consent to participate in this study.\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 20 Years\nMust have maximum age of 75 Years",
"exclusion_criteria": "* 1. The patient is considered to require postoperative chemotherapy other than capecitabine and vinorelbine. 2. The patient has previously been treated with oral 5-FU agents (however, previous treatment with iv 5-FU is acceptable). 3. The patient has either simultaneous or non-simultaneous bilateral breast cancer. 4. The patient has a history of other malignancies or synchronic multiple cancers. However, lesions corresponding to carcinoma in situ or intramucosal carcinoma healed by topical therapy are eligible. 5. The patient is pregnant, has the potential and/or wishes to become pregnant, or is breastfeeding. 6. The patient has previously had an organ transplant. 7. The patient shows hypersensitivity to fluoropyrimidine agents; has previously suffered severe adverse drug reactions with fluoropyrimidine agents; or has a history of serious hypersensitivity to LHRH analogs, tamoxifen, letrozole, anastrozole, and/or exemestane. 8. The patient is currently suffering from serious complications or associated disorders, such as malignant hypertension, congestive heart failure, coronary failure, arrhythmias requiring treatment, infectious diseases, and/or hemorrhagic tendency, and/or has suffered a myocardial infarction within the previous 6 months. 9. The patient has a fever, and there is the possibility that she has an infection. 10. The patient has been shown to have metastasis to other organs. 11. The patient requires treatment for epilepsy and/or central nervous system disorders. 12. The patient is currently being treated for, or has a history of, psychiatric disease. 13. It would be difficult to orally administer drugs to the patient, and/or she suffers from functional insufficiency of the upper gastrointestinal tract and/or malabsorption syndrome. 14. For any other reason, the investigator or sub-investigator has judged the patient to be ineligible for participation.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"identified_line": {
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirement": {
"requirement_type": "status",
"expected_value": "healthy"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirement": {
"requirement_type": "status",
"expected_value": "healthy"
}
}
]
}
},
{
"identified_line": {
"line": "Must be FEMALE",
"criterions": [
{
"exact_snippets": "Must be FEMALE",
"criterion": "gender",
"requirement": {
"requirement_type": "expected_value",
"expected_value": "female"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Must be FEMALE",
"criterion": "gender",
"requirement": {
"requirement_type": "expected_value",
"expected_value": "female"
}
}
]
}
},
{
"identified_line": {
"line": "Must have minimum age of 20 Years",
"criterions": [
{
"exact_snippets": "minimum age of 20 Years",
"criterion": "age",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 20,
"unit": "Years"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "minimum age of 20 Years",
"criterion": "age",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 20,
"unit": "Years"
}
}
}
]
}
},
{
"identified_line": {
"line": "Must have maximum age of 75 Years",
"criterions": [
{
"exact_snippets": "maximum age of 75 Years",
"criterion": "age",
"requirement": {
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 75,
"unit": "Years"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "maximum age of 75 Years",
"criterion": "age",
"requirement": {
"requirement_type": "maximum",
"expected_value": {
"operator": "<=",
"value": 75,
"unit": "Years"
}
}
}
]
}
}
],
"exclusion_lines": [
{
"identified_line": {
"line": "* 1. The patient is considered to require postoperative chemotherapy other than capecitabine and vinorelbine. 2. The patient has previously been treated with oral 5-FU agents (however, previous treatment with iv 5-FU is acceptable). 3. The patient has either simultaneous or non-simultaneous bilateral breast cancer. 4. The patient has a history of other malignancies or synchronic multiple cancers. However, lesions corresponding to carcinoma in situ or intramucosal carcinoma healed by topical therapy are eligible. 5. The patient is pregnant, has the potential and/or wishes to become pregnant, or is breastfeeding. 6. The patient has previously had an organ transplant. 7. The patient shows hypersensitivity to fluoropyrimidine agents; has previously suffered severe adverse drug reactions with fluoropyrimidine agents; or has a history of serious hypersensitivity to LHRH analogs, tamoxifen, letrozole, anastrozole, and/or exemestane. 8. The patient is currently suffering from serious complications or associated disorders, such as malignant hypertension, congestive heart failure, coronary failure, arrhythmias requiring treatment, infectious diseases, and/or hemorrhagic tendency, and/or has suffered a myocardial infarction within the previous 6 months. 9. The patient has a fever, and there is the possibility that she has an infection. 10. The patient has been shown to have metastasis to other organs. 11. The patient requires treatment for epilepsy and/or central nervous system disorders. 12. The patient is currently being treated for, or has a history of, psychiatric disease. 13. It would be difficult to orally administer drugs to the patient, and/or she suffers from functional insufficiency of the upper gastrointestinal tract and/or malabsorption syndrome. 14. For any other reason, the investigator or sub-investigator has judged the patient to be ineligible for participation.",
"criterions": [
{
"exact_snippets": "The patient is considered to require postoperative chemotherapy other than capecitabine and vinorelbine.",
"criterion": "postoperative chemotherapy requirement",
"requirement": {
"requirement_type": "specific drugs",
"expected_value": [
"capecitabine",
"vinorelbine"
]
}
},
{
"exact_snippets": "The patient has previously been treated with oral 5-FU agents (however, previous treatment with iv 5-FU is acceptable).",
"criterion": "previous treatment with oral 5-FU agents",
"requirement": {
"requirement_type": "treatment history",
"expected_value": true
}
},
{
"exact_snippets": "The patient has either simultaneous or non-simultaneous bilateral breast cancer.",
"criterion": "bilateral breast cancer",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "The patient has a history of other malignancies or synchronic multiple cancers. However, lesions corresponding to carcinoma in situ or intramucosal carcinoma healed by topical therapy are eligible.",
"criterion": "history of other malignancies or synchronic multiple cancers",
"requirement": {
"requirement_type": "history",
"expected_value": true
}
},
{
"exact_snippets": "The patient is pregnant, has the potential and/or wishes to become pregnant, or is breastfeeding.",
"criterion": "pregnancy or breastfeeding status",
"requirement": {
"requirement_type": "status",
"expected_value": true
}
},
{
"exact_snippets": "The patient has previously had an organ transplant.",
"criterion": "previous organ transplant",
"requirement": {
"requirement_type": "history",
"expected_value": true
}
},
{
"exact_snippets": "The patient shows hypersensitivity to fluoropyrimidine agents; has previously suffered severe adverse drug reactions with fluoropyrimidine agents; or has a history of serious hypersensitivity to LHRH analogs, tamoxifen, letrozole, anastrozole, and/or exemestane.",
"criterion": "hypersensitivity to specific agents",
"requirement": {
"requirement_type": "hypersensitivity",
"expected_value": [
"fluoropyrimidine agents",
"LHRH analogs",
"tamoxifen",
"letrozole",
"anastrozole",
"exemestane"
]
}
},
{
"exact_snippets": "The patient is currently suffering from serious complications or associated disorders, such as malignant hypertension, congestive heart failure, coronary failure, arrhythmias requiring treatment, infectious diseases, and/or hemorrhagic tendency, and/or has suffered a myocardial infarction within the previous 6 months.",
"criterion": "serious complications or associated disorders",
"requirement": {
"requirement_type": "presence",
"expected_value": [
"malignant hypertension",
"congestive heart failure",
"coronary failure",
"arrhythmias",
"infectious diseases",
"hemorrhagic tendency",
"myocardial infarction within the previous 6 months"
]
}
},
{
"exact_snippets": "The patient has a fever, and there is the possibility that she has an infection.",
"criterion": "fever with possible infection",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "The patient has been shown to have metastasis to other organs.",
"criterion": "metastasis to other organs",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "The patient requires treatment for epilepsy and/or central nervous system disorders.",
"criterion": "treatment for epilepsy or CNS disorders",
"requirement": {
"requirement_type": "treatment requirement",
"expected_value": true
}
},
{
"exact_snippets": "The patient is currently being treated for, or has a history of, psychiatric disease.",
"criterion": "psychiatric disease",
"requirement": {
"requirement_type": "treatment or history",
"expected_value": true
}
},
{
"exact_snippets": "It would be difficult to orally administer drugs to the patient, and/or she suffers from functional insufficiency of the upper gastrointestinal tract and/or malabsorption syndrome.",
"criterion": "difficulty in oral drug administration",
"requirement": {
"requirement_type": "difficulty",
"expected_value": true
}
},
{
"exact_snippets": "For any other reason, the investigator or sub-investigator has judged the patient to be ineligible for participation.",
"criterion": "investigator judgment of ineligibility",
"requirement": {
"requirement_type": "judgment",
"expected_value": "ineligible"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"not_criteria": {
"and_criteria": [
{
"exact_snippets": "The patient is considered to require postoperative chemotherapy other than capecitabine and vinorelbine.",
"criterion": "postoperative chemotherapy requirement",
"requirement": {
"requirement_type": "specific drugs",
"expected_value": [
"capecitabine",
"vinorelbine"
]
}
},
{
"exact_snippets": "The patient has previously been treated with oral 5-FU agents (however, previous treatment with iv 5-FU is acceptable).",
"criterion": "previous treatment with oral 5-FU agents",
"requirement": {
"requirement_type": "treatment history",
"expected_value": true
}
},
{
"exact_snippets": "The patient has either simultaneous or non-simultaneous bilateral breast cancer.",
"criterion": "bilateral breast cancer",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"not_criteria": {
"and_criteria": [
{
"exact_snippets": "The patient has a history of other malignancies or synchronic multiple cancers. However, lesions corresponding to carcinoma in situ or intramucosal carcinoma healed by topical therapy are eligible.",
"criterion": "history of other malignancies or synchronic multiple cancers",
"requirement": {
"requirement_type": "history",
"expected_value": true
}
},
{
"exact_snippets": "The patient has a history of other malignancies or synchronic multiple cancers. However, lesions corresponding to carcinoma in situ or intramucosal carcinoma healed by topical therapy are eligible.",
"criterion": "carcinoma in situ or intramucosal carcinoma healed by topical therapy",
"requirement": {
"requirement_type": "eligibility",
"expected_value": true
}
}
]
}
},
{
"exact_snippets": "The patient is pregnant, has the potential and/or wishes to become pregnant, or is breastfeeding.",
"criterion": "pregnancy or breastfeeding status",
"requirement": {
"requirement_type": "status",
"expected_value": true
}
},
{
"exact_snippets": "The patient has previously had an organ transplant.",
"criterion": "previous organ transplant",
"requirement": {
"requirement_type": "history",
"expected_value": true
}
},
{
"or_criteria": [
{
"exact_snippets": "The patient shows hypersensitivity to fluoropyrimidine agents; has previously suffered severe adverse drug reactions with fluoropyrimidine agents; or has a history of serious hypersensitivity to LHRH analogs, tamoxifen, letrozole, anastrozole, and/or exemestane.",
"criterion": "hypersensitivity to specific agents",
"requirement": {
"requirement_type": "hypersensitivity",
"expected_value": [
"fluoropyrimidine agents",
"LHRH analogs",
"tamoxifen",
"letrozole",
"anastrozole",
"exemestane"
]
}
}
]
},
{
"exact_snippets": "The patient is currently suffering from serious complications or associated disorders, such as malignant hypertension, congestive heart failure, coronary failure, arrhythmias requiring treatment, infectious diseases, and/or hemorrhagic tendency, and/or has suffered a myocardial infarction within the previous 6 months.",
"criterion": "serious complications or associated disorders",
"requirement": {
"requirement_type": "presence",
"expected_value": [
"malignant hypertension",
"congestive heart failure",
"coronary failure",
"arrhythmias",
"infectious diseases",
"hemorrhagic tendency",
"myocardial infarction within the previous 6 months"
]
}
},
{
"exact_snippets": "The patient has a fever, and there is the possibility that she has an infection.",
"criterion": "fever with possible infection",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "The patient has been shown to have metastasis to other organs.",
"criterion": "metastasis to other organs",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "The patient requires treatment for epilepsy and/or central nervous system disorders.",
"criterion": "treatment for epilepsy or CNS disorders",
"requirement": {
"requirement_type": "treatment requirement",
"expected_value": true
}
},
{
"exact_snippets": "The patient is currently being treated for, or has a history of, psychiatric disease.",
"criterion": "psychiatric disease",
"requirement": {
"requirement_type": "treatment or history",
"expected_value": true
}
},
{
"exact_snippets": "It would be difficult to orally administer drugs to the patient, and/or she suffers from functional insufficiency of the upper gastrointestinal tract and/or malabsorption syndrome.",
"criterion": "difficulty in oral drug administration",
"requirement": {
"requirement_type": "difficulty",
"expected_value": true
}
},
{
"exact_snippets": "For any other reason, the investigator or sub-investigator has judged the patient to be ineligible for participation.",
"criterion": "investigator judgment of ineligibility",
"requirement": {
"requirement_type": "judgment",
"expected_value": "ineligible"
}
}
]
}
}
]
}
}
],
"miscellaneous_lines": [],
"failed_inclusion": [
{
"identified_line": {
"line": "* 1. Female patient with primary, infiltrative breast cancer who has been diagnosed on a histological basis. 2. Stage I-IIIB at the first diagnosis and underwent curative resection. 3. The patient was non-pCR after preoperative chemotherapy including anthracycline agents and paclitaxel or docetaxel; that is, she had undergone primary tumor resection and pathologically confirmed to have residual cancer cells.The previously adminstered preoperative chemotherapy must have involved 8 cycles of EC-T or 6 cycles of TEC.If HER-2 is positive, trastuzumab is applied with T chemotherapy 4. The patient has high risk: young;triple negtive breast caner; positive axillary lymphnode;HER-2 positive;ect 5. The patient's general performance status is 0 to 1. 6. The patient must have no carry-over of efficacy from any previous treatment. 7. The patient has maintained sufficient organ function to permit valid evaluation. 8. The patient must have no adverse drug reactions of grade 2 or higher carried over from previous treatment. 9. The patient's creatinine clearance is higher than 50 ml/min 10. The patient has personally given written, informed consent to participate in this study.",
"criterions": [
{
"exact_snippets": "Female patient",
"criterion": "gender",
"requirement": {
"requirement_type": "N/A",
"expected_value": "female"
}
},
{
"exact_snippets": "primary, infiltrative breast cancer",
"criterion": "breast cancer type",
"requirement": {
"requirement_type": "N/A",
"expected_value": "primary, infiltrative"
}
},
{
"exact_snippets": "diagnosed on a histological basis",
"criterion": "diagnosis method",
"requirement": {
"requirement_type": "N/A",
"expected_value": "histological"
}
},
{
"exact_snippets": "Stage I-IIIB at the first diagnosis",
"criterion": "cancer stage",
"requirement": {
"requirement_type": "N/A",
"expected_value": "Stage I-IIIB"
}
},
{
"exact_snippets": "underwent curative resection",
"criterion": "surgical treatment",
"requirement": {
"requirement_type": "N/A",
"expected_value": "curative resection"
}
},
{
"exact_snippets": "non-pCR after preoperative chemotherapy",
"criterion": "pathological complete response",
"requirement": {
"requirement_type": "N/A",
"expected_value": "non-pCR"
}
},
{
"exact_snippets": "preoperative chemotherapy including anthracycline agents and paclitaxel or docetaxel",
"criterion": "chemotherapy regimen",
"requirement": {
"requirement_type": "N/A",
"expected_value": [
"anthracycline agents",
"paclitaxel",
"docetaxel"
]
}
},
{
"exact_snippets": "8 cycles of EC-T or 6 cycles of TEC",
"criterion": "chemotherapy cycles",
"requirement": {
"requirement_type": "N/A",
"expected_value": [
"8 cycles of EC-T",
"6 cycles of TEC"
]
}
},
{
"exact_snippets": "HER-2 is positive, trastuzumab is applied with T chemotherapy",
"criterion": "HER-2 status and treatment",
"requirement": {
"requirement_type": "N/A",
"expected_value": "HER-2 positive, trastuzumab applied"
}
},
{
"exact_snippets": "high risk: young;triple negtive breast caner; positive axillary lymphnode;HER-2 positive",
"criterion": "high risk factors",
"requirement": {
"requirement_type": "N/A",
"expected_value": [
"young",
"triple negative breast cancer",
"positive axillary lymph node",
"HER-2 positive"
]
}
},
{
"exact_snippets": "general performance status is 0 to 1",
"criterion": "performance status",
"requirement": {
"requirement_type": "range",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 0,
"unit": "N/A"
},
{
"operator": "<=",
"value": 1,
"unit": "N/A"
}
]
}
}
},
{
"exact_snippets": "no carry-over of efficacy from any previous treatment",
"criterion": "carry-over efficacy",
"requirement": {
"requirement_type": "N/A",
"expected_value": "none"
}
},
{
"exact_snippets": "sufficient organ function to permit valid evaluation",
"criterion": "organ function",
"requirement": {
"requirement_type": "N/A",
"expected_value": "sufficient"
}
},
{
"exact_snippets": "no adverse drug reactions of grade 2 or higher carried over from previous treatment",
"criterion": "adverse drug reactions",
"requirement": {
"requirement_type": "severity",
"expected_value": "less than grade 2"
}
},
{
"exact_snippets": "creatinine clearance is higher than 50 ml/min",
"criterion": "creatinine clearance",
"requirement": {
"requirement_type": "comparison",
"expected_value": {
"operator": ">",
"value": 50,
"unit": "ml/min"
}
}
},
{
"exact_snippets": "personally given written, informed consent to participate in this study",
"criterion": "informed consent",
"requirement": {
"requirement_type": "N/A",
"expected_value": "given"
}
}
]
},
"logical_structure": {
"exact_snippets": "failed",
"criterion": "failed",
"requirement": {
"requirement_type": "failed",
"expected_value": "failed"
}
}
}
],
"failed_exclusion": [],
"failed_miscellaneous": []
}